NCT03624010View on ClinicalTrials.gov

Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 14, 2018

Primary Completion Date

February 1, 2024

Study Completion Date

February 1, 2024

Conditions
Hypertension Pulmonary Secondary Heart FailureRight Sided Heart Failure With Normal Ejection FractionHeart Failure With Normal Ejection Fraction
Interventions
DRUG

Levosimendan 2.5 mg/ml Injectable Solution

A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion

Trial Locations (9)

15213

UPMC Presbyterian Hospital, Pittsburgh

19104

Hospital of the University of Pennsylvania, Philadelphia

29425

Medical University of South Carolina, Charleston

53792

UW Health University Hospital, Madison

55455

University of Minnesota Medical Center, Minneapolis

55905

Mayo Clinic, Rochester

60611

Northwestern Memorial Hospital, Chicago

68198

University of Nebraska Medical Center, Omaha

94305

Stanford Healthcare, Stanford

All Listed Sponsors
lead

Tenax Therapeutics, Inc.

INDUSTRY

NCT03624010 - Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients | Biotech Hunter | Biotech Hunter